We now have a way to more accurately identify those patients who are not cured with standard treatments, and to direct aggressive and novel therapies accordingly,” said Dr. Max Diehn, a Stanford University professor and co-founder of Foresight. “The unprecedented sensitivity of PhasED-Seq addresses a critical unmet need for how we clinically manage oncology patients. In contrast to existing assays, Foresight’s lymphoma MRD offering is an ‘off-the-shelf’ test that does not require tumor tissue or patient-specific customization. “Foresight’s technology and data demonstrate a level of MRD detection that is more than an order of magnitude better than the nearest competitor, a game changer for the liquid biopsy field,” said Shahram Seyedin-Noor, Founder and General Partner of Civilization Ventures.įoresight will use the financing to enter the commercial phase of development for the PhasED-Seq technology by launching its first CLIA validated assay to support MRD-driven clinical trials in B-cell lymphomas.
Based on a simple blood draw and next-generation sequencing, PhasED-Seq screens for evidence of residual cancer by testing patient plasma samples for the presence of circulating tumor DNA (ctDNA).Īs reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7565 and #8518), PhasED-Seq can detect ctDNA at levels as low as one part-per-million, which is up to 100-times more sensitive than other liquid biopsy-based MRD approaches. Foresight’s approach is based on a proprietary technology developed at and licensed from Stanford University called PhasED-Seq (Phased Variant Enrichment & Detection Sequencing). Foresight Diagnostics today announced the close of its $12.5M Series A financing led by Civilization Ventures and Bluebird Ventures, with participation by Pear Ventures, to commercialize the industry’s most sensitive minimal residual disease (MRD) detection assay.
0 kommentar(er)
